We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-7.32%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.93B
AUM Growth
-$321M
Cap. Flow
-$98.8M
Cap. Flow %
-5.11%
Top 10 Hldgs %
70.83%
Holding
57
New
3
Increased
7
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$153M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$19.4M
3
FOLD
Amicus Therapeutics
FOLD
+$5.75M
4
PHVS icon
Pharvaris
PHVS
+$5.27M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$4.32M

Top Sells

Rank Stock Value
1
INGN icon
Inogen
INGN
+$61.5M
2
HRMY icon
Harmony Biosciences
HRMY
+$44.5M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$36M
4
INZY
Inozyme Pharma
INZY
+$31.8M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 57.28%
2 Financials 8.56%
3 Technology 7.59%
4 Consumer Discretionary 1.65%
5 Communication Services 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$394M
$16M 0.83%
+534,085
New +$19.4M
MIST icon
27
Milestone Pharmaceuticals
MIST
$152M
$14.4M 0.75%
2,530,585
– –
KNTE
28
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$11.5M 0.59%
498,528
+198,528
+66% +$4.32M
DMRA
29
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$8.97M 0.46%
99,912
– –
LUNG icon
30
Pulmonx
LUNG
$87.6M
$8.89M 0.46%
247,047
+60,000
+32% +$2.36M
SPRO icon
31
Spero Therapeutics
SPRO
$73M
$8.63M 0.45%
468,902
– –
CMPI
32
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$8.62M 0.45%
2,170,100
– –
FLXN
33
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.56M 0.44%
1,403,370
– –
AKUS
34
DELISTED
Akouos Inc
AKUS
$8.27M 0.43%
711,945
+252,655
+55% +$3.03M
SILK
35
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$8.12M 0.42%
147,557
– –
TMCI icon
36
Treace Medical Concepts
TMCI
$309M
$7.63M 0.39%
283,769
-39,231
-12% -$1.08M
PHVS icon
37
Pharvaris
PHVS
$2.44B
$7.43M 0.38%
418,943
+307,799
+277% +$5.27M
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
$6.72M 0.35%
442,550
– –
FRLN
39
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$6.58M 0.34%
128,544
-28,871
-18% -$2.05M
AERI
40
DELISTED
Aerie Pharmaceuticals
AERI
$6.33M 0.33%
555,186
– –
NARI
41
DELISTED
Inari Medical, Inc. Common Stock
NARI
$5.86M 0.3%
72,212
– –
INSP icon
42
Inspire Medical Systems
INSP
$1.74B
$4.96M 0.26%
21,300
-24,851
-54% -$5.19M
ALNY icon
43
Alnylam Pharmaceuticals
ALNY
$29.3B
$4.72M 0.24%
25,000
-9,679
-28% -$1.82M
PRAX icon
44
Praxis Precision Medicines
PRAX
$10.1B
$4.62M 0.24%
16,667
-44,030
-73% -$11.9M
VRNA
45
DELISTED
Verona Pharma
VRNA
$4.17M 0.22%
761,205
– –
AFIB
46
DELISTED
Acutus Medical Inc
AFIB
$2.25M 0.12%
255,000
– –
ANNX icon
47
Annexon
ANNX
$886M
$2.13M 0.11%
+114,330
New +$2.32M
HRMY icon
48
Harmony Biosciences
HRMY
$2.24B
$1.53M 0.08%
40,000
-1,382,953
-97% -$44.5M
FSTX
49
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$20K ﹤0.01%
2,703
– –
ABCL icon
50
AbCellera Biologics
ABCL
$2.12B
– –
-422,382
Closed -$9.29M
1
2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q3 2021 Portfolio in Review

As of Q3 2021, Novo Holdings A/S held 57 positions worth $1.93B, down 14% from $2.25B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Novo Holdings A/S withdrew a net $98.8M in Q3 2021, closing 8 positions and reducing 11 holdings. Its most notable exit was Inozyme Pharma, an estimated $31.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 61% a quarter earlier, followed by Financials and Technology.

Against the trend, Novo Holdings A/S opened a new position in Boston Scientific worth $150M.

  • Novo Holdings A/S's largest Q3 2021 buy was Boston Scientific: 3,463,577 shares worth $150M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q3 2021, an estimated $5.75M increase.
  • Novo Holdings A/S's biggest Q3 2021 reduction was Inogen, cutting an estimated $61.5M.
  • Novo Holdings A/S fully exited Inozyme Pharma in Q3 2021, selling an estimated $31.8M.
  • Novo Holdings A/S's ten largest holdings make up 71% of its $1.93B portfolio in Q3 2021.
  • Novo Holdings A/S opened 3 new positions and closed 8 in Q3 2021.
  • Novo Holdings A/S's portfolio value fell 14% quarter-over-quarter to $1.93B.

Based on Novo Holdings A/S's 13F filing for Q3 2021, filed 15 Nov 2021.